Using zwitterionic polyethylene glycol to improve drug delivery
Official title: Zwitterionic polyethylene glycol for therapeutic delivery
Funded at Drexel University · NIH-10945772 · Data updated 2026-11-12
This study is looking at a special type of PEG that could help make biologic drugs and nanomedicines work better by staying in your bloodstream longer, which might lead to improved treatments for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Drexel University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 5, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $318,457 |
| NIH project number | 1R01GM155729-01 |
| Project ID | NIH-10945772 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who require biologic therapies or nanomedicines and may benefit from improved drug delivery methods.
✕Less likely to help
Patients who do not require biologic drugs or nanomedicines may not receive any benefit from this research.
What this research studies
This research investigates the use of zwitterionic polyethylene glycol (PEG) to enhance the delivery and effectiveness of biologic drugs and nanomedicines. By attaching PEG to these therapeutics, the study aims to extend their circulation time in the bloodstream, which can lead to better treatment outcomes. The approach focuses on overcoming challenges posed by anti-PEG antibodies that can reduce the efficacy of PEGylated drugs. Patients may benefit from improved therapeutic options that are less likely to be cleared by the immune system.
Why it matters
Potential benefit: If successful, this research could lead to more effective and longer-lasting treatments for various conditions.
How similar studies have gone: Previous research has shown success with PEGylated therapeutics, indicating a promising avenue for further exploration.
Where this research is happening
-
Drexel University
Philadelphia, United States Active
Researchers
- Principal investigator: Cheng, Hao — Drexel University
- Study coordinator: Cheng, Hao
Related research
Other NIH-funded projects on the same topics.
-
UnityPhilly App to Help Reversal of Overdoses in Philadelphia
A citywide smartphone app helps bystanders link with nearby people who can give naloxone during opioid overdoses in Philadelphia.
-
HIV-1 Tat variation and its link to NeuroHIV health
This research looks at how different HIV-1 Tat protein variants may contribute to neurocognitive problems in adults living with HIV.
-
Longitudinal study of Plasmodium vivax relapses in Central Africa
This study follows people in Central Africa to understand how Plasmodium vivax relapses affect illness and transmission.
-
Linking childhood neurodevelopmental disorders with later-life brain diseases
A large international study will look at whether early conditions like autism and ADHD are linked to higher risk of Alzheimer’s, Parkinson’s, or ALS later in life by analyzing health records and genetic data.
-
Linking developmental disorders with later neurodegenerative diseases
A multinational study will look at how early neurodevelopmental conditions like ASD and ADHD relate to risks of later dementia and other neurodegenerative diseases in adults.
-
Predicting Weight Regain After Weight Loss Through Body Signals
A study with people who are losing weight will check how their body’s metabolism and appetite signals might influence if they regain weight later.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.